Welcome to our dedicated page for Solana Company SEC filings (Ticker: HSDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Solana Company filings document a Delaware issuer with Nasdaq-listed Class A common stock and a business profile that includes a Solana (SOL) digital asset treasury following its history as Helius Medical Technologies. Recent 8-K reports cover operating results, staking-reward revenue, digital-asset fair value effects, capital actions, registered-direct equity financing, put-option arrangements, and outstanding common stock and pre-funded warrants.
Governance filings include director and officer changes, separation and employment arrangements, board composition, and definitive proxy materials for annual-meeting matters, executive compensation, equity awards, and shareholder voting items. The filings also describe the company’s expansion from its medical-device neurotechnology legacy into SOL holdings, staking, custody, and related infrastructure initiatives.
Helius Medical Technologies entered into private placement agreements to sell Cash Securities and Cryptocurrency Securities consisting of shares, pre-funded warrants and stapled warrants priced at $6.881 per share (pre-funded warrants priced at $6.880) with stapled warrants exercisable at $10.134. Cryptocurrency purchasers will pay with Unlocked or Locked SOL tokens; cash purchasers may use USD, USDC or USDT. Cryptocurrency warrants require stockholder approval before issuance for certain shares and the company will call a special meeting as soon as practicable. Pantera and Summer were engaged as strategic advisors and Pantera will also manage the company’s digital assets under a 10-year trading advisory with tiered AUM fees (1.0% to 0.5%). Advisor and PIPE lock-up periods apply and advisor warrants equal to 10% (7% Pantera, 3% Summer) of the Cash and pre-funded warrant shares were issued, with additional performance-based warrants tied to stapled warrant exercises. Summer is controlled by Joseph Chee, who is expected to be named Executive Chairman following closing.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 180,028 shares of Helius Medical Technologies Class A common stock, representing 4.99% of the class. The filing shows shared voting and shared dispositive power over those shares and states Armistice is the investment manager of the direct holder, Armistice Capital Master Fund Ltd., which holds the securities. The Master Fund disclaims beneficial ownership due to its investment management agreement. The reporting persons certify the securities are held in the ordinary course of business and not to change or influence control of the issuer.
L1 Capital Global Opportunities Master Fund, Ltd. reports beneficial ownership of 640 shares of Helius Medical Technologies common stock, comprised of 203 direct common shares and 437 shares underlying warrants. The holding represents 1.01% of the company's outstanding common stock on a post-reverse-split basis, and the filer states sole voting and dispositive power over all 640 shares. The filing references an earlier Schedule that covered 214,050 shares and warrants purchased in the same offering and explains the company completed a 1-for-50 reverse stock split that affected the share counts. Two directors of the reporting fund are named and may be deemed to beneficially own the securities but disclaim such ownership for other purposes.
Helius Medical Technologies (HSDT) received a Schedule 13G/A filed by CVI Investments, Inc. and Heights Capital Management, Inc. The filers state they collectively hold 0 shares, representing 0% of the Class A common stock, and that ownership is at or below the 5% threshold. Heights Capital is identified as the investment manager to CVI and may be deemed to have voting and dispositive power over CVI's shares, while each party disclaims beneficial ownership except for any pecuniary interest.
The filing references a previously filed limited power of attorney and a joint filing agreement and contains no disclosure of an acquisition, disposition, or group control.
Helius Medical Technologies, Inc. (NASDAQ: HSDT) filed an 8-K (Item 8.01) announcing an updated Prospectus Supplement that refreshes its June 2023 at-the-market (ATM) Sales Agreement with Roth Capital Partners. The supplement permits the Company to sell up to US$25 million of registered Class A common stock on Nasdaq or other permitted venues.
• Shares will be issued under the existing S-3 Registration Statement (File No. 333-270433) and qualify as Rule 415(a)(4) “at-the-market offerings.”
• Sales may occur at prevailing or negotiated market prices.
• Use of proceeds: working capital and general corporate purposes, including commercialization and R&D.
• Honigman LLP provided the accompanying legal opinion (Exhibit 5.1) with related consent (Exhibit 23.1).
- The filing does not state how many shares have been sold to date or provide financial metrics.
- No changes to the underlying Sales Agreement terms were disclosed; the update primarily refreshes the prospectus amount.
This 8-K does not constitute an offer to sell securities; it merely notifies investors of the updated prospectus that enables future capital raises via the established ATM facility.